Four cases of ticlopidine-induced cholestatic hepatitis / 대한내과학회지
Korean Journal of Medicine
;
: 557-561, 2002.
Artigo
em Coreano
| WPRIM
| ID: wpr-169315
ABSTRACT
Ticlopidine, a potent antiplatelet agent, is widely used for treatment of coronary artery disease and cerebrovascular disease. Adverse effects has been reported in 10% to 20% of patients receiving ticlopidine. The most commom adverse effects were gastrointestinal disturbance, skin rash, but cholestatic hepatitis with jaundice was rare (0.1% incidence). We have recently experienced four cases of ticlopidine-induced cholestatic hepatitis after coronary artery stent insertion. Jaundice developed within 1 month of starting ticlopidine at recommended daily doses. In all cases, jaundice resolved and serum liver enzymes improved over a period of months after drug withdrawal. Therefore, clinicians should be aware of the reversible condition of ticlopidine-induced cholestatic jaundice that slowly resolves after drug withdrawal.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Doença da Artéria Coronariana
/
Ticlopidina
/
Stents
/
Vasos Coronários
/
Icterícia Obstrutiva
/
Exantema
/
Hepatite
/
Icterícia
/
Fígado
Limite:
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2002
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS